Loading...
XLONBVXP
Market cap209mUSD
Dec 24, Last price  
3,200.00GBP
1D
0.00%
1Q
-18.99%
Jan 2017
137.04%
IPO
437.82%
Name

Bioventix PLC

Chart & Performance

D1W1MN
XLON:BVXP chart
P/E
2,062.92
P/S
1,227.56
EPS
1.55
Div Yield, %
0.05%
Shrs. gr., 5y
0.26%
Rev. gr., 5y
7.93%
Revenues
14m
+6.17%
1,973,5422,383,9712,706,4363,535,3584,333,2215,517,2177,245,8628,751,6089,290,02910,313,57610,930,58811,719,27112,816,22513,606,584
Net income
8m
-3.29%
884,4591,237,1981,521,4541,815,4292,557,4663,494,4284,922,2895,663,3475,861,6637,202,6976,731,3487,674,1518,372,2418,096,717
CFO
9m
+8.13%
766,1391,239,0981,341,1081,765,2902,145,0843,171,7753,956,9375,922,0975,877,4677,723,9826,367,9347,561,6077,903,4508,546,097
Dividend
Apr 11, 202468 GBP/sh
Earnings
Mar 24, 2025

Profile

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.
URL
https://www.bioventix.com/
IPO date
Apr 29, 2014
Employees
12
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
13,607
6.17%
12,816
9.36%
11,719
7.22%
Cost of revenue
3,009
2,771
2,561
Unusual Expense (Income)
NOPBT
10,597
10,045
9,159
NOPBT Margin
77.88%
78.38%
78.15%
Operating Taxes
2,477
1,737
1,582
Tax Rate
23.37%
17.29%
17.27%
NOPAT
8,120
8,308
7,577
Net income
8,097
-3.29%
8,372
9.10%
7,674
14.01%
Dividends
(8,247)
(8,443)
(7,918)
Dividend yield
3.54%
4.15%
4.36%
Proceeds from repurchase of equity
139
BB yield
-0.07%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
(1)
Net debt
(6,426)
(6,326)
(6,737)
Cash flow
Cash from operating activities
8,546
7,903
7,562
CAPEX
(16)
(11)
(12)
Cash from investing activities
(16)
(11)
(12)
Cash from financing activities
(8,247)
(8,304)
(7,918)
FCF
11,760
7,507
6,759
Balance
Cash
5,999
5,716
6,127
Long term investments
427
610
610
Excess cash
5,745
5,685
6,151
Stockholders' equity
10,531
10,592
10,489
Invested Capital
6,257
5,669
4,961
ROIC
136.17%
156.30%
156.53%
ROCE
88.29%
88.32%
82.09%
EV
Common stock shares outstanding
5,297
5,290
5,260
Price
44.00
14.29%
38.50
11.59%
34.50
-13.10%
Market cap
233,065
14.45%
203,646
12.22%
181,464
-13.13%
EV
226,640
197,320
174,727
EBITDA
10,711
10,174
9,302
EV/EBITDA
21.16
19.39
18.78
Interest
303
Interest/NOPBT
0.00%